Comparison of mortality rates in acute myocardial infarction treated by percutaneous coronary intervention versus fibrinolysis-Reference-Cited by-同舟云学术

Comparison of mortality rates in acute myocardial infarction treated by percutaneous coronary intervention versus fibrinolysis

Published:2005-01 Issue:1 Volume:95 Page:100-101
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Betriu Amadeo,Masotti Mónica

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference9 articles.

1. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials;Keeley;Lancet,2003

2. Early revascularization in acute myocardial infarction complicated by cardiogenic shock;Hochman;N Engl J Med,1999

3. Balancing the benefits of primary angioplasty against the benefits of thrombolytic therapy for acute myocardial infarction: the importance of timing;Kent;Eff Clin Pract,2001

4. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything?;Nallamothu;Am J Cardiol,2003

5. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study;Vermeer;Heart,1999

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Time From Distress Call to Percutaneous Coronary Intervention and Outcomes in Myocardial Infarction;JACC: Advances;2024-07

2. 2023 ESC Guidelines for the management of acute coronary syndromes;European Heart Journal: Acute Cardiovascular Care;2023-09-22

3. 2023 ESC Guidelines for the management of acute coronary syndromes;European Heart Journal;2023-08-25

4. Prolonged Reperfusion Delays During the COVID-19 Pandemic: Is Faster Always Better?;Canadian Journal of Cardiology;2022-06

5. First Human Use of RUC‐4: A Nonactivating Second‐Generation Small‐Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point‐of‐Care Treatment of ST‐Segment–Elevation Myocardial Infarction;Journal of the American Heart Association;2020-09